Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Breast Cancer Res Treat ; 133(2): 725-34, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22228431

ABSTRACT

In this study, we analyzed a "variant of uncertain significance" (VUS) located in exon 23 of the BRCA2 gene exhibited by six members of five distinct families with hereditary breast cancer (BC). The variant was identified by DNA sequencing, and cDNA analysis revealed its co-expression with wild-type mRNA. We analyzed co-occurrence with other pathological mutations in BRCA1/2, performed a case-control study, looked for evolutionary data and used in-silico analyses to predict its potential clinical significance. Sequencing revealed an in frame deletion of 126 nucleotides in exon 23, leading to a deletion of 42 amino acids (c.9203_9328del126, p.Pro2992_Thr3033del). All of the VUS-carriers suffered from either BC or ovarian/pancreatic cancer. No other definite pathologic mutation of BRCA genes was found in the five families. The identified deletion could not be observed in a control cohort of 2,652 healthy individuals, but in 5 out of 916 (0.5%) tested BC families without a bona fide pathogenic BRCA1/2 mutation (P = 0.0011). According to these results, the in frame deletion c.9203_9328del126 is a rare mutation strongly associated with familial BC. In summary, our investigations indicate that this BRCA2 deletion is pathogenic.


Subject(s)
Breast Neoplasms/genetics , Genes, BRCA2 , Ovarian Neoplasms/genetics , Sequence Deletion , Amino Acid Sequence , Base Sequence , Case-Control Studies , Computational Biology/methods , Exons , Family , Female , Genes, BRCA1 , Genetic Predisposition to Disease , Humans , Molecular Sequence Data , Mutation Rate , Pedigree
SELECTION OF CITATIONS
SEARCH DETAIL
...